Join BNMS | Print Page | Contact Us | Sign In
Other Guidelines
Other Guidelines
NICE and the BNMS EANM Guidelines DoH Publication

Link to Notes for Guidance on the Clinical Administration of Radiopharmaceuticals and use of sealed radioactive sources, on the ARSAC website January 2022

Published March 2017

Link to guideline

The American Thyroid Association has released Guidelines for the Treatment of Hypothyroidism, which is endorsed by the BNMS.

Please click here to view

The British Thyroid Association has published Guidelines for the Managment of Thyroid Cancer. These can be viewed here

The BTS Guidelines for the investigation and management of pulmonary nodules are now available.

Link to guidelines page here

From the Defra website The Environmental Permitting system simplifies permit applications, amendments and variations for both industry and regulator and thereby cuts unnecessary red tape. It allows regulators to focus resources on medium and high-risk operations whilst continuing to protect the environment and human health.

Environmental Permitting was first applied to Waste Management Licensing and Pollution Prevention and Control and will now be extended to further permitting and compliance regimes. The Environmental Permitting (England and Wales) Regulations 2010 have been approved by Parliament and the National Assembly for Wales and will come into force on 6 April 2010.

Environmental Permitting Guidance Radioactive Substances Regulation For the Environmental Permitting (England and Wales) Regulations 2010 March 2010

Version 1.1

Legislation.gov.uk

A guidance document for Nuclear Medicine departments on how to complete a Safety Assessment as part of the application for, or upgrade to, HSE consent for the Administration of Radioactive Materials to Patients

View the guideline here

This publication is the result of a collaboration the IAEA and Professional Organizations including the EANM, SNMMI, AOFNMB, ALASBINM and WFNMB and a group of internationally renowned experts.

This publication intends to provide practical support for the introduction of new radiotracers, including recommendations on the necessary steps needed to facilitate and expedite the introduction of radiopharmaceuticals in clinical use, while ensuring that a safe and high quality product is administered to the patient at all times.

Please access the freely downloadable PDF at http://www-pub.iaea.org/books/IAEABooks/10829/Good-Practice-for-Introducing-Radiopharmaceuticals-for-Clinical-Use

The Society of Radiographers

Select here

Advice note on in-house software for Nuclear Medicine
View the guideline here

With the rapid expansion of clinical PET-CT in the UK there is an urgent need for guidance on the (state-registered) clinical scientist (CS) support required to deliver the service safely, effectively, in compliance with all relevant regulations, and to the necessary standards set by professional bodies, including ‘Standards for delivering a PET service in the UK’ (Report of the Intercollegiate Standing Committee on Nuclear Medicine, in ‘PET-CT in the UK’, RCR 2005).

These guidelines define the recommended minimum level of clinical scientist support required specifically for PET-CT based on a fixed site and performing FDG oncology studies only. A ‘fixed site’ is a unit where the scanner is permanently installed in a building, and does not include permanently sited mobile units. Additional and specialist scientific and engineering support will be needed where units are operating their own cyclotrons and/or undertaking research. This may be provided in partnership with manufacturers and academic units.

This document has been prepared by a group of clinical scientists from across the UK with extensive experience in PET-CT.

View full document pdf

Reviewed by Claire Greaves 2016

View the Low Iodine cover letter here

View the Low Iodine fact sheet here

This is a joint guideline with BTF (British Thyroid Foundation) and endorsed by BTA (British Thyroid Association)

In August 2004 a Supplement to Heart was published which covered the current applications of myocardial perfusion imaging and also its cost effectiveness and use in clinical practice in the UK. This is a valuable source of information for both providers and users of the technique.

It represents a summary of the evidence on which the submission by the professional bodies to the National Institute of Clinical Excellence (NICE) was based, as part of its development of the health technology assessment of this technique.

Constantinos Anagnostopoulos and Richard Underwood - reviewed by Kshama Wechalekar 2016

Myocardial perfusion scintigraphy: the evidence

C Y Loong and C Anagnostopoulos

Diagnosis of coronary artery disease by radionuclide myocardial perfusion imaging

T M Bateman and E Prvulovich

Assessment of prognosis in chronic coronary artery disease

J E Udelson and E J Flint

Radionuclide imaging in risk assessment after acute coronary syndromes

J J Bax, E E van der Wall, and M Harbinson

Radionuclide techniques for the assessment of myocardial viability and hibernation

S R Underwood and L J Shaw

Myocardial perfusion scintigraphy and cost effectiveness of diagnosis and management of coronary heart disease

S L Rahman and A D Kelion

Nuclear cardiology in the UK: do we apply evidence based medicine?

Click here if you wish to visit the NICE website

The British Nuclear Cardiology Society has released Procedure Guidelines for Radionuclide Myocardial Perfusion Imaging with Single-Photon Emission Computed Tomography (SPECT), which is endorsed by the BNMS.

Please click here to view

Diagnostic Thyroid Guidelines

NICE is updating their guidance for the management of thyroid cancer including the use of I-131. These guidelines are expected in late 2021

Thyroid Therapy

Please note that the British Thyroid Association guideline on the management of thyroid nodules/cancer is advised as the primary source of guidelines in Britain.

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

Published 2016

Link to guideline

Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer

Published February 2016

Link to article

British Thyroid Association Guidelines for the Management of Thyroid Cancer

Published July 2014

Link to guideline

NEW ADDITIONAL LINKS

EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraph
Congenital Hypothyroidism: A 2020–2021 Consensus Guidelines Update—An ENDO-European Reference Network Initiative Endorsed by the European Society for Pediatric Endocrinology and the European Society for Endocrinology

The Medical Exposures Group are delighted to share with you the link to the publication for the “User guidance and national coding taxonomy for incident learning in clinical imaging, magnetic resonance imaging and nuclear medicine”.

Published on the UKHSA website

Select here

 

 

© 2013 BNMS unless otherwise stated.
The BNMS is a registered as a company in England and Wales with number 08082786.  The BNMS is a charity governed by the rules of the Charity Commission for England and Wales - Registered Number 1150234.  Registered Office: The Royal College of Physicians, 11 St. Andrew's Place, Regent's Park, London NW1 4LE.
The British Nuclear Medicine Society is not able to give specific clinical advice to members of the public. If you are concerned about your scan or therapy please seek the opinion of a nuclear medicine clinician where you were seen or the clinician who referred you to the department or your GP.
Enquiries related to issues such as internships and work experience opportunities, should be directed to the relevant professional body e.g., for radiologists, this will be the Royal College of Radiologists.